Chemomab Therapeutics Ltd
NASDAQ:CMMB
Chemomab Therapeutics Ltd
Pre-Tax Income
Chemomab Therapeutics Ltd
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Chemomab Therapeutics Ltd
NASDAQ:CMMB
|
Pre-Tax Income
-$24.2m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Pre-Tax Income
-$7m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
NASDAQ:KMDA
|
Pre-Tax Income
$12.7m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Pre-Tax Income
-$100.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Pre-Tax Income
-$8.9m
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Pre-Tax Income
-₪28.5m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-11%
|
See Also
What is Chemomab Therapeutics Ltd's Pre-Tax Income?
Pre-Tax Income
-24.2m
USD
Based on the financial report for Dec 31, 2023, Chemomab Therapeutics Ltd's Pre-Tax Income amounts to -24.2m USD.
What is Chemomab Therapeutics Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
-28%
Over the last year, the Pre-Tax Income growth was 14%. The average annual Pre-Tax Income growth rates for Chemomab Therapeutics Ltd have been -28% over the past three years .